In order to exclude the impact of EGF and CXCL11 on anlotinib-induced anti-migrating ability (Liang et al. 2021), we added rhCXCL11 and rhEGF to tumor cell with or without anlotinib treatment and found that invasion and migration of ATC cells could hardly be influenced (Supplementary Fig. 1A, B, C and D). The gene discussed is CXCL11; the disease is neoplasm.